Epoprostenol up-regulates serum adiponectin level in patients with systemic sclerosis: therapeutic implications
- 12 January 2021
- journal article
- research article
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 313 (9) , 783-791
Abstract
Introduction Adiponectin, resistin and leptin belong to adipokines, a group of molecules secreted mainly by the adipose tissue, which impaired expression may be a missing link between various manifestations of systemic sclerosis. Adiponectin, which is also released in small amounts by the endothelium, possesses anti-inflammatory, anti-fibrotic and protective against endothelial injury properties. Both leptin and resistin exhibit features which are contradictory to adiponectin, as they trigger inflammation and the activation of skin fibroblasts. Epoprostenol is a prostaglandin analogue with powerful vasodilator activity and inhibitory effect on platelet aggregation. The aim of the study was to evaluate whether epoprostenol may have an effect on serum adipokine levels in patients with systemic sclerosis. Methods A total of 27 patients were included in the study and received epoprostenol intravenously (25 µg of per day for 3 consecutive days). Serum concentrations of total adiponectin, resistin and leptin were assessed with enzyme-linked immunosorbent essay (R&D Systems, Minneapolis, MN, USA). Results In all SSc patients, the basal level of adiponectin was significantly lower compared to healthy controls (mean 6.00 \(\pm \) 2.81 μg/ml vs. 8.8 \(\pm \) 4.3 μg/ml, p = 0.02) and basal level of resistin (mean 11.12 \(\pm \) 3.36 ng/ml vs. 8.54 \(\pm \) 3.07 ng/ml p = 0.02) was significantly higher than in the control group. The serum concentration of adiponectin increased significantly after treatment with epoprostenol (6.00 \(\pm \) 2.81 μg/ml vs 9.29 \(\pm \) 6.05 μg/ml; P = 0.002). The level of resistin and leptin remained unchanged. Conclusion Epoprostenol infusions up-regulate the serum concentration of adiponectin in patients with systemic sclerosis. In our opinion, future studies on treatments in systemic sclerosis should address the issue of their effect on adipokine metabolism.
Keywords
Funding Information
- Warszawski Uniwersytet Medyczny (1M4/N/19/19)
This publication has 64 references indexed in Scilit:
- Prostacyclins2013
- Cultured Preadipocytes Undergoing Stable Transfection with Cyclooxygenase-1 in the Antisense Direction Accelerate Adipogenesis During the Maturation Phase of AdipocytesApplied Biochemistry and Biotechnology, 2013
- Vascular effects of prostacyclin: does activation of PPARδ play a role?Trends in Pharmacological Sciences, 2012
- Adipose Tissue as Regulator of Vascular ToneCurrent Hypertension Reports, 2012
- Adiponectin expression is decreased in the involved skin and sera of diffuse cutaneous scleroderma patientsExperimental Dermatology, 2011
- Regulation of vascular tone by adipocytesBMC Medicine, 2011
- Adiponectin Promotes Revascularization of Ischemic Muscle through a Cyclooxygenase 2-Dependent MechanismMolecular and Cellular Biology, 2009
- Adiponectin is a novel humoral vasodilatorCardiovascular Research, 2007
- Resistin Promotes Endothelial Cell ActivationCirculation, 2003
- Isoproterenol dose-outflow facility response relationships in the vervet monkeyCurrent Eye Research, 1985